Thus, transgenic models, expressing familial AD (FAD) associated mutations in key components of Aβ metabolism [i.e. amyloid precursor protein- APP and/or presenilins (PS) genes) and tau (MAPT)] have been developed [reviewed in [1]]. This evidence concerns the gene APP and familial Alzheimer disease.